Stock AB AB SCIENCE
Add to a list
To use this feature you must be a member
Log inSign up

Financials AB Science

Equities

AB

FR0010557264

Pharmaceuticals

Market Closed - Euronext Paris
Other stock markets
 11:35:15 2024-04-26 am EDT 		5-day change 1st Jan Change
1.936 EUR +2.76% Intraday chart for AB Science -1.63% -45.54%
Apr. 04 AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada MT
Apr. 03 AB Science: reconsideration possible for masitinib in ALS CF

Valuation

Fiscal Period: December 2018 2019 2020 2022 2023 2024 2025
Capitalization 1 142.4 237 895.3 332.2 98.86 98.86 -
Enterprise Value (EV) 1 142.4 237 895.3 332.2 98.86 98.86 98.86
P/E ratio - - - -24.4 x -5.09 x -5.38 x -5.23 x
Yield - - - - - - -
Capitalization / Revenue 83.7 x 151 x 566 x - 106 x 99.9 x 89.9 x
EV / Revenue 83.7 x 151 x 566 x - 106 x 99.9 x 89.9 x
EV / EBITDA - - - - -5.18 x -5.53 x -5.26 x
EV / FCF - - - - -5.26 x -5.5 x -5.2 x
FCF Yield - - - - -19% -18.2% -19.2%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 41,064 44,060 45,540 46,861 51,067 51,067 -
Reference price 2 3.468 5.380 19.66 7.090 1.936 1.936 1.936
Announcement Date 4/30/19 4/30/20 4/30/21 3/1/23 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2022 2023 2024 2025
Net sales 1 1.701 1.571 1.583 - 0.93 0.99 1.1
EBITDA 1 - - - - -19.1 -17.89 -18.78
EBIT 1 - -17.47 - - -15.96 -15.91 -15.8
Operating Margin - -1,112.29% - - -1,716.13% -1,607.07% -1,436.36%
Earnings before Tax (EBT) - - - - - - -
Net income 1 - - - -13.62 -19.64 -18.77 -18
Net margin - - - - -2,111.83% -1,895.96% -1,636.36%
EPS 2 - - - -0.2900 -0.3800 -0.3600 -0.3700
Free Cash Flow 1 - - - - -18.81 -17.99 -19
FCF margin - - - - -2,022.58% -1,817.17% -1,727.27%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 4/30/19 4/30/20 4/30/21 3/1/23 - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - - - -18.8 -18 -19
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 0.48 - - - 0.05 0.06 0.5
Capex / Sales 28.45% - - - 5.38% 6.06% 45.45%
Announcement Date 4/30/19 4/30/20 4/30/21 3/1/23 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.936 EUR
Average target price
6.895 EUR
Spread / Average Target
+256.15%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
AB SCIENCE Stock AB Science
-45.54% 106M
MERCK KGAA Stock Merck KGaA
+5.31% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
INDIVIOR PLC Stock Indivior PLC
+18.82% 2.38B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AB Stock
  4. Financials AB Science